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Advances in laboratory techniques have led to a rapidly
increasing use of biomarkers in epidemiological studies.
Biomarkers of internal dose, early biological change,
susceptibility and clinical outcomes are used as proxies
for investigating interactions between external and / or
endogenous agents and body components or processes. The
need for improved reporting of scientific research led to
influential statements of recommendations such as the
STrengthening Reporting of OBservational studies in
Epidemiology (STROBE) statement. The STROBE initia-
tive established in 2004 aimed to provide guidance on how
to report observational research. Its guidelines provide
a user-friendly checklist of 22 items to be reported in
epidemiological studies, with items specific to the three
main study designs: cohort studies, case–control studies
and cross-sectional studies. The present STrengthening the
Reporting of OBservational studies in Epidemiology –
Molecular Epidemiology (STROBE-ME) initiative builds
on the STROBE statement implementing nine existing
items of STROBE and providing 17 additional items to the
22 items of STROBE checklist. The additions relate to the
use of biomarkers in epidemiological studies, concerning
collection, handling and storage of biological samples;
laboratory methods, validity and reliability of biomarkers;
specificities of study design; and ethical considerations.
The STROBE-ME recommendations are intended to
complement the STROBE recommendations.
Introduction
In recent years, advances in laboratory techniques have led to
a rapidly increasing use of biomarkers in epidemiological-
studies, a field known as molecular epidemiology (1–5).
Biomarkers are any substance, structure or process that can be
measured in biospecimens and may be associated with health-
related outcomes. Biomarkers of internal dose, of early
biological change, and of susceptibility (see Fig. 1 and Box 1
for definitions) are used as proxies for investigating the
interplay between external and / or endogenous agents and the
body. Biomarkers may provide valuable scientific tools
because of their ability to inform biological mechanisms
through the examination of early, intermediate and late
molecular and cellular events. Moreover, a biomarker may
capture several external exposure variables in a single bi-
ologically relevant quantity, provide quantitative measure-
ments, increase statistical power or be used as an efficient and
informative intermediate outcome. Finally, biomarkers can be
used to identify susceptible individuals and to improve
diagnosis and early detection of disease as well as prediction
of major clinical outcomes in patients with a given disease.
Figure 1 describes the whole spectrum of applications of
biomarkers; the scheme uses cancer as an example because this
is the field in which the conceptual framework of molecular
epidemiology has had the greatest development and numerous
postulated potential applications; however, similar concepts
apply to many other fields.
Biomarker-based measurements are not, however, problem
free. As in classical biomedical and epidemiological research,
considering methodological issues concerning the design,
conduct, analysis and interpretation of the results is essential
to adequately address a research question (6). In addition to the
usual problems of bias and confounding that affect all clinical
and epidemiological studies, particular issues when using
biomarkers include (i) validity and reliability of biomarker
measurements, (ii) special sources of bias, (iii) reverse causality
and (iv) false positives as a result of multiple testing or selective
reporting. To conceive relevant and valid studies, in biomarker-
based research, we need an in-depth understanding and
integration of methodological and substantive (i.e. biological,
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clinical and environmental) knowledge. Complete, accurate and
transparent reporting of study design, methods, conduct and
findings is required to allow the study to be fairly and adequately
evaluated and summarized including avoidance of selective
reporting of positive results (7–10). Empirical evidence suggests
that the results of the most highly cited biomarker studies across
medicine almost consistently report larger effect estimates than
those reported in subsequent meta-analyses (11). Suboptimal
reporting may also lead to inflated expectations on the
translational potential and clinical utility of findings (12). At
the other end of the spectrum, false negatives are also a common
problem (9), and they may result from limited sample size, poor
study design or inappropriate laboratory assays (13).
The need for improved reporting of scientific research in
general led to influential statements of recommendations such
as CONSORT for randomized controlled trials (14,15) and
STrengthening Reporting of OBservational studies in Epide-
miology (STROBE) statement (16). The STROBE initiative
was established in 2004 aiming at providing guidance on how
to report observational research. The resultant STROBE
statement was simultaneously published in several medical
journals in 2007 (16,17). Its guidelines provide a user-friendly
checklist of 22 items to be reported in epidemiological studies,
with items specific to the three main study designs: cohort
studies, case–control studies and cross-sectional studies. The
STROBE statement has had an important impact. Its recom-
mendations were adopted by several journals, and there is
evidence that they have affected the style of result reporting
(18). However, there is also evidence of misuse of the
STROBE statement (19).
Recent advances in molecular biology and the vast amount
of data generated by high-throughput techniques (and consequent
changes and improvement in terms of epidemiology, statistical
analysis and study design) warrant implementing the STROBE
recommendations specifically for molecular epidemiology
studies. For a review of the state of the art of molecular
epidemiology and the ensuing methodological problems, see (1).
Molecular tools (biomarkers) are also increasingly applied in
epidemiology because of new and difficult issues that are
addressed, such as the effects of chronic low-level exposures.
While important discoveries of the past – such as the role of
cholesterol or tobacco smoking – originated from studies with
strong associations identified based on single measurements,
there is now a challenge to identify weaker associations, and
these require more accurate and sensitive tools. This increases the
importance of a meticulous, comprehensive and transparent
description of studies involving biomarkers.
Herein, we propose an extension of STROBE, i.e. STROBE
for molecular epidemiology, STROBE-ME. The guidelines
aim to provide an easy-to-use checklist of items that authors
may use for reporting molecular epidemiology studies other
than genetic association studies.
Recommendations already exist for genetic association
studies, a field that has specific characteristics and require-
ments of reporting which have been included in a separate
recent statement (STREGA, an extension of STROBE) (20).
There is some necessary overlap between the current guide-
lines and STREGA, insofar as ‘susceptibility biomarkers’
are included in the present recommendations. Communication
of results of molecular epidemiology studies is a still
underdeveloped field. This paper refers only to scientific
communication of study results and does not address the
ethical problem of communicating results to single individ-
uals, see (21,22).
Aims and use of the STROBE-ME statement
The expected outcome of the present recommendations is an
improvement in the reporting of results, such that the editors,
reviewers of papers and the readers understand better what
was actually done by the authors. STROBE-ME is expected
to lead to more organized and transparent papers and to
a better understanding of both the strengths and weaknesses
of the studies in molecular epidemiology. Our recommenda-
tions do not dictate how studies should be performed nor do
they serve as a basis to evaluate the quality of observational
studies; they only try to help improve the reporting of
Fig. 1. Schematic framework on the use of biomarkers in molecular epidemiology studies. Adapted from Vineis and Perera (42).
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research. The adoption of improved reporting standards may
nevertheless have also an indirect benefit on the quality of
study design.
The parent STROBE statement is a checklist of 22 items to
be addressed when observational epidemiological studies are
reported. The STROBE items cover different aspects of
reporting a study: the title (one item), introduction (two items),
methods (nine items), results (five items), discussion (four
items) and funding of research (one item) (16). The explanation
and elaboration document of STROBE (17) explains these
items in detail and provides good real-life examples in
published works for their application.
The statement proposed here is intended to be an extension
of the STROBE statement for molecular epidemiology studies.
The present recommendations are intended only for those
studies in which biomarkers are used as an explanatory
variable; these include biomarkers of exposure / internal dose,
biomarkers of early biological change and biomarkers of
susceptibility (Box 1, and Fig. 1). This set of biomarkers is
used as measurable proxy for the process of the interaction
Box 1. Definitions of terms used in the text
There are several definitions of biomarkers. The most commonly adopted states that a biomarker is any substance or
biological structure that can be measured in the human body and may influence, explain or predict the incidence or outcome
of disease (24). According to another definition, a biomarker is ‘a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention’(43).
Biomarkers are measured in human biospecimens typically using molecular, biochemical and cytogenetic techniques. Some
investigators also include under the biomarker umbrella measures derived from modern imaging techniques that aim to
characterize biological process, e.g. from positron emission tomography or functional magnetic resonance imaging.
However, these biomarkers also entail issues that are specific to image processing and interpretation that are beyond the
scope of the guidance provided in this manuscript. Some biomarkers (but not ‘exposure biomarkers’) allow insight into the
cellular processes in the human body and serve to explore the links among environmental / endogenous exposures, the
genome, host factors / structures and disease. Based on the concept that there is continuity between exposure to an external
agent, its metabolism within the body and the onset of a resulting time-delayed disease, we can distinguish three main types
of biomarkers that are able to investigate the internal process of interaction between the external agent and the body (Fig. 1).
A biomarker of exposure / internal dose is an indicator of current and / or past exposure to environmental agents. Biomarkers of
internal dose may indicate, depending on their nature, a recent or very recent exposure as well as a long-term exposure. The ideal
biomarker of exposure is specific, detectable at very low concentrations, in quantitative relationship with the level of exposure, and its
levels integrate over time.
Metabolite concentrations change rapidly with a short half-life from a few hours up to a few days and may show a large daily intra-
individual variation as well as inter-individual variation. They may be specific for certain exposures or integrate several types of
exposure. For example, urinary 1-hydroxypyrene concentration is a surrogate for the measurement of complex PAH exposure via
different exposure routes, whereas urinary 4-(methylnitrosamino)-1-(3-pyridinyl)-1-butanol (NNAL), a metabolite of 4-
(methylnitrosamino)-1-(3-pyridinyl)-1-butanone (NNK), and its glucuronides are specific biomarkers of exposure to tobacco smoke.
A wide variety of highly sensitive analytical methods are used for the detection of parent compounds and their metabolites in human
biospecimens.
Biomarkers of early biological change are biomarkers that reflect the interaction between the external agent and the exposed
body. They usually encompass a broad and heterogeneous category; their main advantage is that their presence in subjects is usually
more frequent than the disease itself and they can be detected earlier, thus allowing researchers to identify potential harm before
a clinical disease manifests. Biomarkers of early biological change include markers of early detection of disease and also prognostic
markers if the outcome is death, recurrence or disability.
Biomarkers of susceptibility include multiple subcategories, which encompass both acquired (phenotypic) biomarkers and
genotypic markers (2). Examples of the former are biomarkers of previous disease, whereas genotypic markers include the more
extensively studied category of inherited genetic variants. Concerning the latter, an essential issue is whether and how gene
variants manifest themselves in cellular functions and phenotypes and how they influence individual susceptibility to
environmental exposures. These include also cellular phenotypes (such as DNA repair capacity) applied to study differences in
repair capacity in healthy exposed populations (44). There are ethnic and geographical differences in the frequency distribution of
genetic variants. Various technologies have been developed for low- and high-throughput genotyping. Additionally, markers of
acquired susceptibility need to be considered, such as biomarkers of previous diseases or biomarkers of previous exposures such
as epigenetic changes.
Biomarkers can also be used for the prediction of the clinical course and outcomes of disease under natural history or under
treatment. Although these clinical uses are usually outside the scope of traditional aetiological research, this is a very rapidly
expanding literature (45–47,23) with major challenges. Although the current recommendations could apply to these uses, for
tumour marker prognostic studies, the reader should refer to the REMARK guidelines (7).
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between an external/endogenous agent and the body at
different biological levels. Other study designs involving
biomarkers are not covered by the present recommendations,
including transitional studies of validation and reliability of
measurement.
Some items belonging to the original STROBE checklist
have been implemented for molecular epidemiology studies;
other items have been added de novo to the original checklist.
The 10 implemented items include issues on study design
specificities in molecular epidemiology studies; description of
relevant participant conditions at the time of sample collection;
and particular statistical aspects if the biomarker measurements
are introduced into statistical models. The seven new specific
items added to the original STROBE checklist include
biological sample collection, storage and processing; and the
laboratory methods used for the analyses. The present extended
checklist was developed as an extension of the STROBE
checklist (Table 1). The recommendations are intended to
complement the existing STROBE guidelines, not to replace
them; therefore, all previously described items concerning
observational studies such as cohort, case–control and cross-
sectional studies apply to molecular epidemiological studies
(when appropriate).
The present statement contains a checklist of items for
reporting molecular epidemiology studies (Table 1); some
explanatory text referring to single item description; and some
Boxes in which specific aspects of molecular epidemiology are
briefly addressed for readers’ reference. Although the current
recommendations could apply also to biomarkers used for the
prediction of clinical course and outcomes of disease, for
tumour marker prognostic studies the reader should refer to the
REMARK guidelines (7).
Concerning the uses of the present statement, additional
details on how the parent STROBE statement was used can be
found on the website (http://www.strobe-statement.org/). It is
expected that the statement will be adopted and referred to by
journals that publish molecular epidemiology papers, as well as
by journals that publish clinical research in which biomarkers
have an important role (23).
Development of the STROBE-ME statement
A multidisciplinary group of epidemiologists, biostatisticians
and laboratory scientists (overall approximately 15 scientists)
developed the current recommendations. Also, editors of
several specialist journals were involved from the outset. The
group met twice in London (UK) in 2008 and 2009, once in
Turin (Italy) in 2009 and once in qo´dz´ (Poland) in 2010; it
sought external opinions from partners of the Environmental
Cancer Risk, Nutrition, and Individual Susceptibility (ECNIS)
European Network of Excellence – which was the initiator of
the STROBE-ME initiative. Overall, the process lasted 3 years.
While no formal process such as a Delphi consultation was used
for development, consensus was built by circulating several
versions of the statement within the group of developers and an
external circle of potential users. In all, over 30 scientists were
involved in the process.
Checklist of items
The items that should be considered when reporting molecular
epidemiology studies are shown in Table 1. These items are
similar to those that were originally recommended in STROBE,
however, with modifications that are specific to molecular
epidemiology. Later, we give a detailed description of each
item. The purpose is not to suggest how to set up a research
project but how to improve reporting of the research to allow
readers (and reviewers) to better understand what was actually
done by the researchers.
ME-1 – State the use of biomarker(s) in the title and/or in the
abstract if they contribute substantially to the findings
When one or more biomarkers are measured in an
epidemiological study, it may be more informative reporting
this in the title or at least in the abstract of the article. This
helps the reader to identify immediately molecular epidemi-
ology studies and ensures a correct indexing in electronic
databases.
ME-2 – Explain in the scientific background of the paper how /
why the specific biomarker(s) have been chosen, potentially
among many others
The process leading to the choice of one or more specific
biomarkers for inclusion in a paper should be made clear in the
Introduction. Background information and rationale for the
choice of the specific biomarker(s) should be explicitly stated;
also, how the biomarker is introduced in the study design
should be made explicit (biomarker of exposure, internal dose,
early biological change and susceptibility). It should also be
clarified whether the biomarker is used as a proxy, and if so,
what it is intended to be a proxy for.
ME-3 – A priori hypothesis: if one or more biomarkers are used
as proxy measures, state the a priori hypothesis on the expected
values of the biomarker(s)
When stating the objective(s) of a study according to the
STROBE guidelines (16), it might be helpful to state explicitly
the a priori hypothesis on the expected values of the
biomarker(s).
ME-4 – Describe the special study designs for molecular
epidemiology (in particular nested case–control and case–
cohort) and how they were implemented
Study design details should be reported in the Methods
section. For traditional designs such as case–control, cohort
and cross-sectional studies, the STROBE recommendations
can be followed, with extra care in reporting the biological
sample collection integration within study design; for
nested case–control and case–cohort studies, selection
criteria for cases and controls, sampling frame and matching
criteria should be reported with extra care, as they represent
a main potential source of bias in these study designs (see
Box 2). In addition to matching criteria for individuals, all
methods used for selecting or matching biological samples
(i.e. by storage time and by batch) should be reported. Also,
it is recommended to describe briefly the cohort in which
nested studies were implemented, in terms of description of
the population, sampling, outcome ascertainment, follow-up
period, number of subjects lost to follow-up and primary
objective for which the cohort was established.
ME-4.1 – Report on the setting of the biological sample
collection; amount of sample; nature of collecting procedures;
participant conditions; time between sample collection and
relevant clinical or physiological endpoints
An accurate description of the sample collection and shipment
is necessary to enable the reader to evaluate potential sources
V. Gallo et al.
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Table 1. The STrengthening in Reporting OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME) Reporting Recommendations:
Extended from STROBE statement
Item Item number STROBE Guidelines Extension for Molecular Epidemiology
Studies (STROBE-ME)
Title and abstract 1 (a) Indicate the design of the study with
a commonly used term in the title or the
abstract
ME-1 State the use of specific biomarker(s)
in the title and / or in the abstract if they
contribute substantially to the findings
(b) Provide in the abstract an informative and
balanced summary of what was done and
what was found
Introduction
Background rationale 2 Explain the scientific background and
rationale for the investigation being reported
ME-2 Explain in the scientific background of
the paper how / why the specific
biomarker(s) have been chosen, potentially
among many others (e.g. others are studied
but reported elsewhere or not studied at all)
Objectives 3 State specific objectives, including any pre-
specified hypotheses
ME-3 A priori hypothesis: if one or more
biomarkers are used as proxy measures, state
the a priori hypothesis on the expected values
of the biomarker(s)
Methods
Study design 4 Present key elements of study design early in
the paper
ME-4 Describe the special study designs for
molecular epidemiology (in particular, nested
case / control and case / cohort) and how they
were implemented
Biological sample collection ME-4.1 Report on the setting of the
biological sample collection; amount of
sample; nature of collecting procedures;
participant conditions; time between sample
collection and relevant clinical or
physiological endpoints
Biological sample storage ME-4.2 Describe sample processing
(centrifugation, timing, additives, etc.)
Biological sample processing ME-4.3 Describe sample storage until
biomarker analysis (storage, thawing,
manipulation, etc.)
Biomarker biochemical characteristics ME-4.4 Report the half-life of the biomarker
and chemical and physical characteristics
(e.g. solubility)
Setting 5 Describe the setting, locations and relevant
dates, including periods of recruitment,
exposure, follow-up and data collection
Participants 6 (a) Cohort study – Give the eligibility criteria
and the sources and methods of selection of
participants. Describe methods of follow-up
Case–control study – Give the eligibility
criteria and the sources and methods of case
ascertainment and control selection. Give the
rationale for the choice of cases and controls
Cross-sectional study – Give the eligibility
criteria and the sources and methods of
selection of participants
ME-6 Report any habit, clinical condition,
physiological factor or working or living
condition that might affect the characteristics
or concentrations of the biomarker
(b) Cohort study – For matched studies, give
matching criteria and number of exposed and
unexposed
Case–control study – For matched studies,
give matching criteria and the number of
controls per case
Variables 7 Clearly define all outcomes, exposures,
predictors, potential confounders and effect
modifiers. Give diagnostic criteria, if
applicable
Data source / measurement 8 For each variable of interest, give sources of
data and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than one
group
ME-8 Laboratory methods: report type of
assay used, detection limit, quantity of
biological sample used, outliers, timing in the
assay procedures (when applicable) and
calibration procedures or any standard used
Bias 9 Describe any efforts to address potential
sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were
handled in the analyses. If applicable,
describe which groupings were chosen and
why
STROBE-ME
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Table 1. Continued
Item Item number STROBE Guidelines Extension for Molecular Epidemiology
Studies (STROBE-ME)
Statistical methods 12 (a) Describe all statistical methods, including
those used to control for confounding
ME-12 Describe how biomarkers were
introduced into statistical models
(b) Describe any methods used to examine
subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study – If applicable, explain how
loss to follow-up was addressed
Case–control study – If applicable, explain
how matching of cases and controls was
addressed Cross-sectional study – If
applicable, describe analytical methods
taking account of sampling strategy
(e) Describe any sensitivity analyses
Validity/reliability of measurement and
internal/external validation
ME-12.1 Report on the validity and
reliability of measurement of the
biomarker(s) coming from the literature and
any internal or external validation used in the
study
Results
Participants 13 (a) Report the numbers of individuals at each
stage of the study – e.g. numbers potentially
eligible, examined for eligibility, confirmed
eligible, included in the study, completing
follow-up and analysed
ME-13 Give reason for loss of biological
samples at each stage
(b) Give reasons for nonparticipation at each
stage
(c) Consider use of a flow diagram
Descriptive data 14 (a) Give characteristics of study participants
(e.g. demographic, clinical and social) and
information on exposures and potential
confounders
(b) Indicate the number of participants with
missing data for each variable of interest
(c) Cohort study – Summarize follow-up
time (e.g. average and total amount)
Distribution of biomarker measurement ME-14.1 Give the distribution of the
biomarker measurement (including mean,
median, range and variance)
Outcome data 15 Cohort study – Report numbers of outcome
events or summary measures over time
Case–control study – Report numbers in each
exposure category or summary measures of
exposure
Cross-sectional study – Report numbers of
outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if
applicable, confounder-adjusted estimates
and their precision (e.g. 95% confidence
interval). Make clear which confounders
were adjusted for and why they were
included
(b) Report category boundaries when
continuous variables were categorized
(c) If relevant, consider translating estimates
of relative risk into absolute risk for
a meaningful time period
Other analyses 17 Report other analyses done – e.g. analyses of
subgroups and interactions and sensitivity
analyses
Discussion
Key results 18 Summarize key results with reference to
study objectives
Limitations 19 Discuss limitations of the study, taking into
account sources of potential bias or
imprecision. Discuss both direction and
magnitude of any potential bias
ME-19 Describe main limitations in
laboratory procedures
Interpretation 20 Give a cautious overall interpretation of
results considering objectives, limitations,
multiplicity of analyses, results from similar
studies and other relevant evidence
ME-20 Give an interpretation of results in
terms of a priori biological plausibility
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of bias or errors in the biomarker measurement and for
ensuring an appropriate reproducibility of the scientific
experiment (see Box 3). The following items should be
reported: (i) the setting of the biological sample collection
(place, time of the day, time of the year, laboratories involved,
personnel involved, etc.); (ii) amount/volume/size of sample(s);
(iii) nature of the collecting procedure (anticoagulant involved,
e.g. heparin, EDTA) (iv) if the participant is healthy,
participant condition at the sample collection (fasting status,
position, etc.) when appropriate; (v) if participants are not
healthy individuals in stable physiological conditions, then
report the relevant aspects of the health status and clinical
conditions of the participants (24,25); (vi) in all instances,
consider reporting the time between sample collection and
relevant clinical or physiological endpoints that might have
affected the characteristics or concentrations of the biomarker
(26). In particular, report any relevant characteristic of the
participants, which might influence the biomarker levels in any
known or unknown way. For example, position of the study
subjects, such as orthostatism decreases plasma volume, so that
Table 1. Continued
Item Item number STROBE Guidelines Extension for Molecular Epidemiology
Studies (STROBE-ME)
Generalizability 21 Discuss the generalizability (external
validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the
funders for the present study and, if
applicable, for the original study on which
the present article is based
Ethics ME-22.1 Describe informed consent and
approval from ethical committee(s). Specify
whether samples were anonymous,
anonymized or identifiable
Box 2. Specificities of study design for molecular epidemiology: nested case–control studies and case–cohort studies
Molecular epidemiology uses the same study designs as the general epidemiology, but some variants are more common. In
particular, case–control studies nested in cohorts and case–cohort studies are frequently used to avoid extensive and costly
measurements in large cohorts. In nested case–control studies derived from established cohorts, controls are usually matched
for age and sex, and also for time variables related to sample collection and disease onset. The method of control selection in
these studies is ‘‘incidence density’’ sampling, and an incidence risk ratio is estimated. Controls may develop the disease of
interest subsequently to the diagnosis of the case, but they represent the cohort set at risk of developing the disease when each
case occurs (24). The criteria for case inclusion and control matching and selection and their rationale should be reported (1).
In case–cohort studies, unmatched controls come from a sample of the cohort at inception without being matched to cases on
time to outcome. The method for control selection in these studies is based only on the population at baseline, without regard to
failure times, and a risk ratio is estimated (24,1).
Both study designs share the important feature that cases and controls come from the same cohort study: recall bias is not of
concern if exposure assessment was carried out before disease onset; non-participation bias is avoided because rapidly fatal
cases have the same probability of inclusion as others; and reverse causation becomes less likely as biological samples were
collected before the onset of the clinically documented disease. The nested case–control study tends to be more efficient than
the case–cohort study in selecting controls to address confounding. In case–cohort studies, however, the same sample of
controls can be compared to different samples of cases (thus different outcomes can be studied). Also, as the subcohort is
a random sample of the whole cohort, prevalence of exposure can be estimated and external comparisons can be made.
The main concerns regarding nested case–control studies are that controls are not representative of the cohort population and they
have few other uses, so the investment in biomarker analyses cannot be leveraged for other research. On the other hand, case–
cohort studies rely on the assumption that exposure can be equally well measured in the subcohort as in the cases. However, three
issues regarding biomarker validity make this assumption questionable: batch effects, the storage effect and freeze–thaw cycles.
There are technological and staffing limits to how many samples can be analysed in one go so samples are run in batches or
groups. Conditions of the analyses should not vary by batch, but it is clear that for many biomarker measurements this is not true,
i.e. there are substantial batch effects (laboratory variation). Also, not all biomarker targets are stable at the usual storage
temperature (80 C), and when samples freeze and thaw, the pH and ionic balance of the liquid phase of the sample can be very
different from the natural condition of the sample. Changes in pH and ionic balance can degrade biomarker targets. For these
reasons, it may be necessary to include matching by length of storage, batch and freeze–thaw cycles (1).
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proteins and cholesterol levels can be lowered by 5–15%
relative to the supine position.
Detailed information on all critical steps that might have
altered the biological samples or influenced the final biomarker
measurement should be identified and reported accordingly in
the Methods section.
ME-4.2 – Describe sample processing (centrifugation, timing,
additives, etc.)
A comprehensive description of all steps of sample process-
ing is needed in the Methods section to assess experimental
reproducibility. This description ranges from manual han-
dling of samples to specific machinery used for laboratory
processing (see Box 3). When a well-established technique is
used, the main process can be referred to by quoting the
article where the technique is described and any variation
from the initially described laboratory technique should be
explicitly stated.
ME-4.3 – Describe sample storage until biomarker analysis
(storage, thawing, manipulation, etc.)
Particularly in nested case–control and case–cohort studies,
biomarkers can be measured in biological samples stored for
extended durations; sometimes, samples may have already
undergone freeze–thaw cycles. As these processes can partially
alter the biomarker values under examination, it is important to
report in the Methods section any manipulation that the
biological samples may have undergone, together with a de-
tailed description of how the samples were stored.
ME-4.4 – Report the half-life of the biomarker and chemical
and physical characteristics (e.g. solubility)
For new biomarker(s) only, some basic biochemical information
relevant to the interpretation of the measured values should be
reported in the Methods section. This includes biochemical
andbiophysical characteristics that might be relevant when
interpreting the results, such as half-life, solubility or lipophilicity.
ME-6 – Report any habit, clinical condition, physiological
factor, or working or living condition that might affect the
characteristics or concentrations of the biomarker
Report any relevant characteristic of the participants, which
might influence the biomarker levels in any known or unknown
way (24). For example, exposure to air pollution (27) or
seasonality (28) might influence DNA adduct levels in healthy
subjects; similarly, type of diet (29,30) or amount of sunlight
exposure (28,31) might influence DNA damage biomarkers in
healthy subjects.
ME-8 – Laboratory methods: report type of assay used,
detection limit, quantity of biological sample used, outliers,
timing in the assay procedures (when applicable) and
calibration procedures or any standard used
The methods used in the laboratory for biomarker analyses
should be described in detail in a dedicated section of the
Methods. Particular care should be taken to describe new or
modified techniques, while for a well-established technique,
the main process can be referred to by quoting the article where
the technique is described, and any variation from the initially
Box 3. Collection, handling and storage of biological samples
Several types of human biospecimens can be collected for carrying out molecular epidemiology studies. Blood samples may be
stored as a whole or separated into subfractions and blood components (red blood cells, serum, plasma, buffy coat and white
blood cell subfractions). White blood cells contained in the buffy coat are the most widely used source of DNA. Urine can be
used as a solution of excreted parent compounds and metabolites to be measured, or as a source of exfoliated cells of the
urinary tract. Collection and primary processing are performed accordingly. Other human tissue specimens used in molecular
epidemiology studies include body fluids (i.e. cerebrospinal fluids), cell washes (i.e. buccal wash or swabs), epithelial smears,
surgical material, nails and hair. Each step in collection, storage, thawing, manipulation and laboratory analysis can introduce
errors that may lead to bias and variability. Random error, if evenly distributed in study subgroups, is likely to attenuate or
eliminate differences. Systematic errors (e.g. differential clinical conditions, handling or storage of biological samples from
cases and noncases) may generate spurious associations.
Timing of collection often influences the true biomarker level. For example, hormones have hourly, daily or monthly cycles.
Prolonged venipuncture can induce release of prolactin or increase white blood cell counts. A very narrow needle causes
haemolysis. Several additives can be added to blood, e.g. metaphosphoric acid for vitamin C; anticoagulants such as heparin,
EDTA or citrate are needed for plasma collection (i.e. not needed if only serum is collected). There may be disadvantages:
heparin binds to many proteins and influences T-cell proliferation; EDTA interferes with cytogenetic analyses. Citrate-stabilized
blood affords better quality of RNA and DNA than other anticoagulants. Other additives include protease inhibitors and RNAse
inhibitors to avoid degradation of proteins and RNA, respectively.
The goals of a proper sample storage are to ensure (i) standardized procedures for all phases; (ii) minimal loss or degrading of
material (e.g. because of malfunctioning of freezers); (iii) optimal preservation of material; (iv) blinding, whenever appropriate; (v)
easy access to the material when needed; (vi) easy matching of biological material with individual identity; (vii) respect of
confidentiality; and (viii) anticipation of emergencies. Stability of the compounds to be measured depends on the type of
measurement and temperature of storage: for example, fatty acids should be measured within 2 weeks when samples are stored at 4
C, within a few months when stored at)20 C, up to one year when stored at)80 C. A few studies have been conducted on the
stability of different analytes, but the literature is far from being exhaustive.
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described laboratory technique should be explicitly stated. Any
calibration procedures or external standards used in the
laboratory (or for comparing data coming from different
laboratories) should also be described. The definition of
‘outlier’ should be clearly given (for example, whether it is
based on pathophysiological, technical or statistical grounds).
ME-12 – Describe how biomarkers were introduced into
statistical models
Usually, statistical methods that apply to biomarkers do not
differ from those used in other branches of epidemiology and
clinical research. Here, we mainly refer to specificities of
biomarker research. When continuous variables are used (a
Box 4. Biomarker validity and reliability
In order to achieve an accurate estimate of the association between biomarker and a disease, reliable and valid measurements of
exposure, covariates (potential confounders and effect modifiers) and outcomes are needed (48). Validity is defined as the
(relative) lack of systematic measurement error when comparing the actual observation with a standard, which is a reference
method representing the ‘truth’. While validity entails a ‘standard’, reliability (reproducibility and repeatability) concerns the
extent to which any measuring procedure yields the same results in repeated experiments (49).
Validity and reliability are separate entities: a measurement may be perfectly reliable (reproducible in different laboratories
and repeatable at different times), but consistently wrong, i.e. far away from the true value; conversely, another one can be
unbiased on average, but unreliable if the measurements scatter widely around a true value. Both validity and reliability are
important; however, as validity is often not measurable, reliability is sometimes used (incorrectly) as a surrogate.
Timing is also a relevant aspect: inferences about the meaning of biomarker measures are often strictly time specific, as time
influences the results in several different ways (49). For example, while DNA genetic variants are the same for each individual
through one’s life time, their epigenetic profile may change markedly over time.
Biomarker variability influences associations with the endpoint, thus needs to be assessed and reported upon. A single
measure of a biomarker for one individual will be affected by (i) variability within subject (intra-subject); (ii) biological
sample variation (i.e. variation depending on the frame of biological sample collection); and (iii) laboratory variation.
1)Intra-individual variation is sometimes so large that between-individual variation (usually the unit of interest) is hard to detect.
A single biological measurement (assume that this is in the absence of laboratory variation) represents the biomarker level/
status at a particular time. The biomarker may undergo diurnal, monthly, seasonal or longer variations, e.g. prolactin has
a circadian rhythm, oestrogens vary through the menstrual cycle, biomarkers related to recent fruit and vegetable intakes may
have seasonal variations. Other biomarkers are more stable, i.e. have less intra-individual variation, and thus, a single measure/
sample is usually sufficient (such as mercury in hair, SNPs – single nucleotide polymorphisms). Variation in exposure to other
compounds may have influence on the marker level. Intra-individual variability can be measured only if repeated samples
from the same individual are collected (50). Depending on the research question, a measure of a recent, short-term or
instantaneous level may be desired (e.g. current CD4 count in a HIV patient), or an average level over a specified time interval
(e.g. usual vitamin D level).
2)Biological sampling variation is related to the circumstances of biological sample collection. For example, hyperproliferation of
colonic cells is extremely variable at different segments of the colon mucosa. Therefore, not only the intra-subject variation over
time is important, because of the varying exposure to agents that induce cell proliferation, but also the measurements are strongly
influenced by how and where the mucosa is sampled from.
3) Laboratory measurements can have many sources of error, in particular two general classes of laboratory errors: those that occur
between analytical batches and those that occur within the batches. Handling, processing and storing of specimens may contribute
to errors. Laboratory procedures need to be in place to minimize such variation and avoid biases. Quality control procedures such
as the inclusion of laboratory quality control samples and blinded split samples are used to assess the extent of these errors. There
should be no identifiers that relate the sample to any other characteristics of the individual from whom it came and in particular of
their disease status or any other factor.
The errors of biomarker measurement may have different impact depending on their error distribution. If the epidemiological
study has been conducted blindly, i.e. the laboratory analyses have been carried out with no knowledge of the exposed/
unexposed or diseased/healthy status of the subjects, the measurement error is expected to be evenly distributed across strata of
exposure or disease. However, this is true only if the error is equally distributed across the scale of the exposure. This kind of
misclassification leads to underestimation of the risk ratio because of a ‘blurring’ of the relationship between exposure and
disease. Both underestimation and overestimation of the association of interest may occur when misclassification is not evenly
distributed across the study variables (51). Individuals with extreme biomarker levels may be excluded, or sensitivity analyses
are carried out with and without them to check whether they overly influence the general findings.
The most important single measure of biomarker reliability is the intra-class correlation coefficient (ICC). This is a quantitative
measurement of the between-person variance divided by the total (between- plus within-subject) variance (52). It describes how
strongly measurements taken in the same subject resemble each other in comparison with the inter-individual variance.
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very common occurrence for biomarkers), testing for linearity
may be useful when the marker is used as a covariate, in
addition to checking other statistical model assumptions when
it is used as an outcome. Statistical manipulation of a variable
derived from biomarker measurement values should be
described in detail as for other variables included in the
statistical models. Whether the variable is introduced as
a continuous or categorical variable (and if categorical what
criterion has been used for identifying cut-off points); whether
extreme values have been excluded, and with which criteria;
whether the original variable has been log transformed or
manipulated in any other way; whether crude measurements or
corrected/adjusted values (e.g. ratios to binding hormones and
creatinine-adjusted values) were analysed; and how samples
with nondetectable biomarker levels were dealt with (e.g.
considered as zero, as the detection limit, as half of that level or
imputed) should be clearly stated.
ME-12.1 – Report on the validity and reliability of
measurement of the biomarker(s) coming from the literature
and any internal or external validation used in the study
Validity and reliability of biomarker(s) measurement should be
reported when every specific biomarker is introduced (see Box
4). Measurement error has several components, and there is
ambiguity on the use of the term, because ‘error’ encompasses
both true ‘variations’ and ‘mistakes’. ‘Analytical’ measurement
errors originate from the laboratory technique(s), including
between-batch variation, while other sources of ‘pre-analytical
error’ include variations in the individuals or the samples that
are investigated (1). Ideally, the inter-individual, intra-individual
Box 5. Ethical considerations
Legal issues related to the use of stored human biological material are contained in a European guideline issued by the Council
of Europe (http://www.coe.int). In the United States, a useful website is http://nih.gov/sigs/bioethics. When incorporating
biospecimen-derived measurements, the following requirements should be met: follow respectful protocols in eliciting
information; avoid harm to participants; secure proper informed consent, manage anonymization of interlinking databases;
establish confidentiality and security safeguards; develop proper responses to requests for personal data by various parties;
devise sound data access, ownership and intellectual property policies; be clear about whether and how individuals will be
informed of findings that might be medically helpful for them; and arrange supervision by research ethics and privacy
protection bodies (53).
Clearly, each of these requirements would need extensive comments. In particular, how ‘broad’ should the consent be? On the
one hand, a broad consent (e.g. ‘the biological samples will be used for the identification of gene variants that may predispose
to chronic diseases’) implies a greater freedom of the researcher, who is not obliged to collect further consent forms each time
a new gene is investigated. On the other hand, such a generic informed consent form explains very little to the recruitees.
The concept of informed consent was initially formulated in the Declaration of Helsinki in 1964, with the latest revision in
2000 (http://www.wma.net). Recent developments in molecular epidemiology tend to overcome the conflict between ‘broad’ and
‘narrow’ consent forms, introducing the idea of a ‘two-level consent’, i.e. a relatively broad procedure at first, followed by
a more specific and detailed approach when studies on single genes/biomarkers are conducted.
For example, there is a broad agreement that low-penetrant variants that are common in the general population and are
associated with a slight increase in the risk (interacting with environmental exposures) should not be subject to strict rules as
far as ethical implications are concerned. In fact, knowledge of presence or absence of a single allele involved in metabolic
pathways neither allows the carrier to modify her / his risk profile substantially nor allows the researcher to identify other
members of the family, which would violate confidentiality. The case of highly penetrant gene variants is different: e.g. the
identification of the carrier of a rare mutation allows the researchers to identify other family members possibly affected, with
potential detrimental effects (e.g. on insurance policies).
The same reasoning applies to biomarkers. The majority of biomarkers used in observational epidemiological research are of
little utility to the subjects participating in the research, when taken alone. This is particularly true for the biomarkers of
exposure, but also some biomarkers of early biological change/effect may not be meaningful when extrapolated from the
research context; for example, DNA adduct level is difficult to interpret at a personal level. Researchers should have a clear
view of the practical implications of testing for the study subjects, and in particular what to do in each of these situations: when
no effective treatment is possible; when treatment is available with close balance of favourable/unfavourable effects; and
effective treatment is available with scarce unfavourable effects. Similar considerations apply to biomarkers, which can be
weakly or strongly associated with diseases and less or more associated with family history.
Anonymization of information is another difficult issue. First, there is a problem of definitions: ‘identifiable’ is a sample with
name or social security number on it; ‘coded’ is a sample with a code that allows relatively easy identification of the person;
‘encrypted’ is a sample with a code that does not allow easy identification of the person, but this is possible with extra effort;
finally, ‘anonymous’ is a sample for which there is no possibility of linking to a person. Clearly, a really anonymous collection
of samples is of very little use for epidemiological research, which is based on follow-up and linkage of laboratory data and
health-related data.
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and inter-laboratory variations should be reported for each
biomarker to enable the reader to understand the potential
source of error for each specific biomarker. Literature-based
reliability estimates should be properly referenced. When these
figures are not available from the literature, this should also be
stated. If aspects of the validity and reliability have been
determined as part of the current study, the methods and process
should be briefly stated. When a specific laboratory procedure
or method for biomarker measurement has been standardized
across laboratories for facilitating the comparability, this should
be clearly stated (32,33).
Biomarker measurement validation is particularly important
when a new biomarker is described. Without information on
measurement error, intra-individual variation and inter-in-
dividual variation biomarker studies are uninterpretable. Also,
variation by batch is usually very relevant and may create
artifactual relationships (34). For more detailed presentation of
validity and reliability issues, see Box 4.
Besides validity and reliability of biomarker measurements,
it is increasingly recognized that the study results are likely to
be more credible when they have been reproduced by some
additional validation process, either internally (e.g. by cross-
validation) or preferably with external independent validation
in samples that are totally different from those where the
biomarker was first tested (35). All attempts at internal and
external validation carried out by the authors should be
reported in detail in the Methods section, and the respective
results should be shown in the Results section.
ME-13 – Give reasons for the loss of biological samples at
each stage
Loss of specimens, nonevaluable samples (because of poor
quality) or assay failures are common occurrences. When some
samples are not included in the final analysis because of
problems in sample quality, quantity, availability, timing of
sample collection or technical failure give detailed reasons.
This will help in tracking the final sample size and the reasons
for sample exclusions.
ME-14.1 – Give the distribution of the biomarker measurement
(including mean, median, range and variance)
An appropriate description of the biomarker measurement
distribution is of help for interpreting results and for comparing
similar biomarker measurements by other scientists. It also
often facilitates the biological interpretation of the results. A
graph of the full distribution may be useful (when relevant, also
by exposure status or case / control status).
ME-19 – Describe main limitations in laboratory procedures
Potential and actual limitations met in laboratory procedures
should be described in detail in the Discussion. It may be
helpful also to report whether the limitation would likely have
introduced a random or systematic error and, if systematic, to
suggest in which direction this might have biased the results.
Validation of results of biomarker studies is of major
importance, and the discussion should address whether any
validation procedure was used in the study (36).
ME-20 – Give an interpretation of results in terms of a priori
biological plausibility
Results should be interpreted in the light of the mechanism(s)
of action of the biomarker(s) and of the a priori hypothesis,
thus offering a biologically plausible interpretation. It may be
useful to stress the added value of the biomarker(s) in
explicating the biological mechanism underlying the associa-
tion reported.
ME-22.1 – Describe informed consent and approval from
ethical committee(s). Specify whether samples were
anonymous, anonymized or identifiable
Molecular epidemiology poses special ethical issues that are
summarized in Box 5.
Discussion
Transparent reporting is essential in epidemiology as in science
in general, and in molecular epidemiology in particular. Given
that the use of biomarkers has raised great expectations in terms
of potential elucidation of disease aetiology and pathogenesis, it
is important to raise awareness on the intrinsic limitations of
biomarker measurements. In particular, measurement error is
a common problem and can cause both false-negative and false-
positive results (9). Also, the lack of a formal study design may
substantially impair the interpretation of the results, and selective
reporting of results can be detrimental.
The present STROBE-ME checklist should strengthen
primarily the reporting and interpretability of molecular
epidemiology studies, if used widely and systematically. It
has been developed based on two strong foundations: (i) the
well-established STROBE collaboration and the related
statement and (ii) an ECNIS working group formed by
epidemiologists, biostatisticians and laboratory scientists with
extensive experience in the field of molecular epidemiology
and biomarker analyses.
We hope that these guidelines will improve the quality of
reporting of molecular epidemiology and other biomarker-
based research, including studies conducted within the growing
number of biobanks and of biomonitoring projects. The ethical
duty of researchers includes reporting findings with accuracy,
completeness and transparency, and in sufficient detail to allow
the scientific community to consider them adequately, assess
their strengths and weaknesses and make fair comparisons.
Well-reported published studies can contribute to and be
summarized with an evidence-based approach in an appropriate
manner (i.e. on sound scientific grounds) to arrive at unbiased
conclusions that lead to better knowledge and the advancement
of citizens’ health (37,38).
Finally, we would like to stress that these recommendations,
as the original STROBE statement and other guidelines on
reporting research (7,14,16,20), are evolving documents
requiring continuous feedback, reassessment and refinement.
The STROBE-ME guidelines will be published on the
STROBE website (http://www.strobe-statement.org) where
a forum for discussion and improvement of the checklist and
related material will be available.
Guidance documents should also be appraised for their eventual
impact. The EQUATOR initiative (39–41) has found that only
17% of the surveyed guideline developers performed a formal
evaluation of the impact. We will engage journal editors in attempts
to evaluate the impact of the present statement in the long run.
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